The Effects of Glucagon on Hepatic Metabolism

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

Whether impaired postprandial glucagon suppression in prediabetes and T2DM is an attempt to overcome resistance to glucagon's actions on hepatic AA catabolism, a defect in α-cell function, or a combination of both are important, unanswered questions. NAFLD is associated with T2DM risk and impaired insulin action. Unfortunately, it is unclear if glucagon resistance is caused by obesity, hepatic steatosis or both. The experiments outlined will determine if glucagon's actions on hepatic amino acid catabolism and EGP interact with hepatic lipid metabolism in lean and obese subjects with and without T2DM (and with varying degrees of hepatic steatosis).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 25
Maximum Age: 65
Healthy Volunteers: t
View:

• Willing to participate

• Able to give consent

Locations
United States
Minnesota
Mayo Clinic in Rochester
RECRUITING
Rochester
Contact Information
Primary
Jeanette Laugen
Laugen.Jeanette@mayo.edu
5072558110
Time Frame
Start Date: 2022-10-20
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 60
Treatments
Experimental: Healthy Adults
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
Experimental: Obese Adults
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
Experimental: Adults with Type 2 Diabetes
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
Sponsors
Leads: Adrian Vella

This content was sourced from clinicaltrials.gov

Similar Clinical Trials